Minagene's test utilizes targeted next-generation sequencing and array-based platforms to comprehensively detect somatic mutations, chromosomal rearrangements, and gene expression signatures in leukemia, lymphoma and myeloma specimens.



DNA and RNA are extracted from bone marrow, peripheral blood or tissue samples and processed for hybrid capture-based targeted sequencing of over 300 genes recurrently implicated in hematological cancers. Custom FISH/aCGH panels interrogate recurring translocations.

Key Highlights of Minagene’s Molecular Testing for Hematological Malignancies

Key Highlights of Minagene’s Molecular Testing for Hematological Malignancies

-Establishes definitive diagnoses for ambiguous morphologies

-Determines prognostic risk stratification and subtype classification

-Identifies targets for specific small molecule inhibitors and immunotherapies

-Monitors for minimal residual disease during and after treatment

-Features a CLIA-certified, CAP-accredited laboratory

By applying a multimodal genomic approach, clinicians can optimize therapeutic strategies from diagnosis through remission monitoring. Comprehensive mutational profiling assists clinical decision-making at all stages of care.

When to Consider Minagene’s Molecular Testing for Hematological Malignancies

Physicians should order Minagene’s molecular testing at initial workup of suspected hematological cancers as well as during surveillance and relapse to elucidate resistance mechanisms, guide clinical trial selection, and personalize management.


Minagene's panel utilizes hybrid capture-based next-generation sequencing to simultaneously evaluate over 500 cancer-related genes from solid tumor specimens. This identifies clinically relevant genomic alterations to guide targeted therapy selection.


Tumor DNA

Tumor DNA undergoes library preparation prior to enrichment of all coding exons across key oncogenes and tumor suppressors. Paired formalin-fixed paraffin-embedded and frozen tissue is supported. Whole exome sequencing is available based on indications.

Key Highlights of

Minagene’s NIPT

1. Comprehensive Fetal Genome Analysis:

-Interrogates both common and rare driver mutations

-Detects microsatellite instability and tumor mutational burden

-Determines homologous recombination deficiency status

-Identifies comprehensive genomic profiles

-Supports enrollment in matched clinical trials

By applying an unbiased genomic approach, clinicians gain a thorough understanding of pathogenic alterations to maximize treatment effectiveness through precision medicine paradigms.

When to Consider Minagene’s Comprehensive Tumor Gene Panel

Physicians should order Minagene's comprehensive panel for advanced solid tumors, particularly where standard therapies have failed, to guide selection of matched targeted agents and immunotherapies.

Your compare list